What Is the Forecasted Market Size of the Radioligand Therapy Market by 2029?
The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the rise in liquid biopsy usage, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the growing pipeline of bispecific antibodies, and the increase in government funding for cancer.
The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising investments by big pharma in oncology startups, increasing utilization of real-world evidence, growth in radiopharmaceutical and theranostics research, growing partnerships between academia and industry, and rising prevalence of rare and orphan cancers. Major trends in the forecast period include AI-driven radiopharmaceutical design, theranostics with dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.
Claim your free report sample now:
Which Drivers Are Positively Impacting the Radioligand Therapy Market?
The increasing cancer incidence is expected to propel the growth of the radioligand therapy market going forward. Cancer is a disease marked by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. Cancer incidence is rising due to long-term exposure to environmental pollutants that damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in January 2022, according to the American Cancer Society, a US-based cancer awareness non-profit organization, in the US, an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths are expected, reaching up to approximately 1,670 deaths on daily basis. Therefore, the increasing cancer incidence is driving the growth of the radioligand therapy market.
Which Are the Leading Segments in the Radioligand Therapy Market by Revenue?
The radioligand therapy market covered in this report is segmented
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)
How Are Innovation and Technology Shaping the Future Trends of the Radioligand Therapy Market?
Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.
Who Are the Top Companies Contributing to the Radioligand Therapy Market Expansion?
Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.
Get the full radioligand therapy market report here:
How Are Market Trends Differentiating Across Key Regions in the Radioligand Therapy Market?
North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment